1,708
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Takeda's recently active trials. Comparator arms are excluded.
- Soticlestat14 trials
- Zasocitinib8 trials
- TAK-9356 trials
- Mezagitamab4 trials
- Elritercept4 trials
- Vedolizumab3 trials
Upcoming readouts
Next primary completion dates among Takeda's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Nov 2026A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)Phase 2
- Nov 2026A Study of TAK-360 in Adults With Idiopathic HypersomniaPhase 2
- Feb 2027A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Particip…Phase 2
- May 2027A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesPhase 3
- May 2027A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With…Phase 3
- Oct 2027A Study of Zasocitinib in Adults With Nonsegmental VitiligoPhase 2
Top therapeutic areas
Conditions studied most often across Takeda's recently active trials.
- Crohn's Disease9 trials
- Ulcerative Colitis6 trials
- Dravet Syndrome (DS)6 trials
- Lennox-Gastaut Syndrome (LGS)4 trials
- Narcolepsy Type 14 trials
- Epilepsy3 trials
Takeda pipeline by phase
The main study drugs across 83 active trials Takeda leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 319 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| ZasocitinibTAK-279 | 12 | 9 | Feb 2027 est. | NCT07752108 · NCT07286058 · NCT07250802 |
| ElriterceptTAK-226 | 6 | 6 | Feb 2028 est. | NCT07623161 · NCT07422480 · NCT06499285 |
| Mezagitamab | 4 | 3 | Mar 2028 est. | NCT06963827 · NCT06948318 · NCT06722235 |
| Fazirsiran Injection | 3 | 2 | Aug 2028 est. | NCT06165341 · NCT05899673 · NCT05677971 |
| MobocertinibTAK-788 | 3 | — | Oct 2026 est. | NCT04129502 · NCT03807778 · NCT02716116 |
| Maribavir | 2 | 2 | Dec 2026 est. | NCT06439342 · NCT05319353 |
| TAK-755 | 2 | 1 | Mar 2027 est. | NCT04683003 · NCT07392450 |
| TAK-861 | 2 | 1 | Oct 2026 est. | NCT07363720 · NCT05816382 |
| TAK-881 | 2 | 1 | May 2028 est. | NCT06747351 · NCT06076642 |
| TDV | 2 | 2 | Apr 2027 est. | NCT06665035 · NCT06579755 |
| Vonicog Alfa | 2 | 2 | Nov 2027 est. | NCT07129343 · NCT05582993 |
| IGI, 10% | 1 | 1 | Sept 2028 est. | NCT06980480 |
| Ponatinib | 1 | — | — | NCT03589326 |
| TAK-330 | 1 | 1 | Aug 2028 est. | NCT05156983 |
| TAK-928 | 1 | 1 | Nov 2028 est. | NCT07217301 |
| Teduglutide | 1 | — | Feb 2027 est. | NCT06973304 |
| Tetravalent Dengue Vaccine (TDV) | 1 | — | — | NCT07047521 |
| Vedolizumab SC | 1 | 1 | Aug 2030 est. | NCT06405087 |
| Vortioxetine tablets | 1 | 1 | Sept 2029 est. | NCT07204314 |
Phase 25 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| TAK-360 | 4 | 4 | Nov 2026 est. | NCT07646678 · NCT07633301 · NCT06952699 |
| Rusfertide | 2 | 1 | Oct 2027 est. | NCT07765602 · NCT07648030 |
| Idursulfase-IT | 1 | — | Jan 2029 est. | NCT06031259 |
| TAK-007 | 1 | — | — | NCT05020015 |
| TAK-411 | 1 | 1 | Dec 2027 est. | NCT06798012 |
Phase 15 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| AskBio009 | 1 | — | Jan 2030 est. | NCT01687608 |
| TAK-188 | 1 | 1 | Dec 2028 est. | NCT07205718 |
| TAK-505 | 1 | 1 | Aug 2030 est. | NCT07436728 |
| TAK-781 | 1 | 1 | Apr 2028 est. | NCT07229911 |
| TAK-853 | 1 | — | — | NCT06390995 |
Phase 47 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Vedolizumab IV | 6 | 5 | May 2027 est. | NCT06581328 · NCT06100289 · NCT05837897 |
| Vedolizumab | 5 | 4 | Jun 2027 est. | NCT06095128 · NCT06045754 · NCT06443502 |
| Brentuximab vedotin | 3 | 1 | Mar 2028 est. | NCT06831370 · NCT05673785 · NCT02979522 |
| CDPATH™ | 1 | — | — | NCT04809363 |
| Fruquintinib | 1 | 1 | Oct 2027 est. | NCT06562543 |
| Replagal | 1 | 1 | Oct 2027 est. | NCT05067868 |
| TAK-664 | 1 | — | Dec 2027 est. | NCT07794735 |
Derived from 83 active trials Takeda leads; 83 name an intervention, folding into 36 phased drugs. 3 interventions carry no registry phase (observational studies, tests and devices) and are not shown. This is ComplyRx's reading of the registry, not Takeda's own pipeline disclosure.
Takeda trials
The 50 most significant of Takeda's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| HYPNOSEpidemiology of Narcolepsy Type 1 and Type 2 in SpainNCT07299097 | — | Not yet scored | OngoingActive, not recruiting | 402 est. | 30 Sept 2026 |
| A Trial of TAK-861 for the Treatment of Narcolepsy With CataplexyNCT07363720TAK-861 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 98 est. | 2 Oct 2026 |
| A Survey of Lanadelumab in Participants With Hereditary AngioedemaNCT05397431Lanadelumab | — | Not yet scored | OngoingActive, not recruiting | 155 est. | 27 Oct 2026 |
| A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access ProgramNCT07429942 | — | Not yet scored | OngoingNot yet recruiting | 94 est. | 30 Oct 2026 |
| A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)NCT06952699TAK-360 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 88 est. | 30 Nov 2026 |
| A Study of TAK-360 in Adults With Idiopathic HypersomniaNCT06812078TAK-360 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 96 est. | 30 Nov 2026 |
| A Study on Infections in Adults With Ulcerative Colitis/Crohn's DiseaseNCT07250815 | — | Not yet scored | OngoingNot yet recruiting | 23,900 est. | 15 Dec 2026 |
| A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South KoreaNCT06550882OBIZUR | — | Not yet scored | OngoingRecruiting | 9 est. | 31 Dec 2026 |
| Post-Marketing Study of Prucalopride Safety In PregnancyNCT04869280 | — | Not yet scored | OngoingActive, not recruiting | 125 est. | 1 Feb 2027 |
| A Study of Teduglutide in Chinese Adults With Short Bowel SyndromeNCT06973304Teduglutide | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 13 est. | 10 Feb 2027 |
| A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseNCT06233461TAK-279 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 268 est. | 17 Feb 2027 |
| PANORAMAA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community SettingNCT06581328Vedolizumab IV | Phase 4 | Locked · track to reveal | OngoingRecruiting | 200 est. | 1 May 2027 |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesNCT06671483Zasocitinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,088 est. | 18 May 2027 |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic MedicinesNCT06671496Zasocitinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 600 est. | 18 May 2027 |
| A Study of Zasocitinib in Adults With Non-pustular Palmoplantar PsoriasisNCT07752108Zasocitinib | Phase 3 | Not yet scored | OngoingNot yet recruiting | 40 est. | 30 May 2027 |
| A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's DiseaseNCT06045754Vedolizumab | Phase 4 | Locked · track to reveal | OngoingRecruiting | 50 est. | 28 Jun 2027 |
| A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)NCT06095128Vedolizumab | Phase 4 | Locked · track to reveal | OngoingRecruiting | 65 est. | 9 Jul 2027 |
| A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal CancerNCT06562543Fruquintinib | Phase 4 | Locked · track to reveal | OngoingRecruiting | 78 est. | 4 Oct 2027 |
| A Study of Zasocitinib in Adults With Nonsegmental VitiligoNCT07108283Zasocitinib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 200 est. | 12 Oct 2027 |
| A Study of Rusfertide in Japanese Adults With Polycythemia VeraNCT07648030Rusfertide | Phase 2 | Not yet scored | OngoingRecruiting | 9 est. | 28 Oct 2027 |
| A Study of Replagal in Children and Adults With Fabry Disease in IndiaNCT05067868Replagal | Phase 4 | Locked · track to reveal | OngoingRecruiting | 5 est. | 31 Oct 2027 |
| A Study of TAK-664 in People With Primary Immunodeficiency Diseases Who Have Not Yet Been Treated With ImmunoglobulinsNCT07794735TAK-664 | Phase 4 | Not yet scored | OngoingNot yet recruiting | 9 est. | 1 Dec 2027 |
| A Study of TAK-755 in Adults With Acute Ischemic StrokeNCT07392450TAK-755 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 222 est. | 6 Dec 2027 |
| A Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaNCT06722235Mezagitamab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 171 est. | 16 Mar 2028 |
| A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's DiseaseNCT07403968Zasocitinib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 20 est. | 30 Mar 2028 |
| A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in PolandNCT07623174 | — | Not yet scored | OngoingNot yet recruiting | 110 est. | 31 Mar 2028 |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsNCT06499285Elritercept | Phase 3 | Locked · track to reveal | OngoingRecruiting | 225 est. | 1 May 2028 |
| A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's DiseaseNCT06100289Vedolizumab IV | Phase 3 | Locked · track to reveal | OngoingRecruiting | 70 est. | 16 May 2028 |
| A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia ANCT06461533Susoctocog Alfa (Genetical Recombination) | — | Not yet scored | OngoingRecruiting | 25 est. | 31 May 2028 |
| A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic SyndromesNCT07319845TAK-226 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 42 est. | 26 Jun 2028 |
| A Survey of Maribavir Tablets in Participants With Cytomegalovirus InfectionNCT06577363Maribavir | — | Not yet scored | OngoingRecruiting | 250 est. | 30 Jun 2028 |
| A Study of Rusfertide in Adults With Polycythemia Vera in ChinaNCT07765602Rusfertide | Phase 2 | Not yet scored | OngoingNot yet recruiting | 24 est. | 1 Jul 2028 |
| A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyNCT06963827Mezagitamab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 347 est. | 7 Sept 2028 |
| A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaNCT06980480IGI, 10% | Phase 3 | Locked · track to reveal | OngoingRecruiting | 183 est. | 11 Sept 2028 |
| Gaucher Disease Outcome Survey (GOS)NCT03291223 | — | Not yet scored | OngoingRecruiting | 1,257 est. | 30 Sept 2028 |
| MarsLight-11A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung CancerNCT07217301TAK-928 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 600 est. | 1 Nov 2028 |
| A Study of TAK-188 in Adults With Advanced or Spreading Solid TumorsNCT07205718TAK-188 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 223 est. | 26 Dec 2028 |
| A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney TransplantNCT07613359Mezagitamab | Phase 2 | Locked · track to reveal | OngoingNot yet recruiting | 36 est. | 15 Jan 2029 |
| ELRiSE MDSA Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsNCT07422480Elritercept | Phase 3 | Locked · track to reveal | OngoingRecruiting | 300 est. | 30 Apr 2029 |
| A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaNCT06948318Mezagitamab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 150 est. | 29 Jul 2029 |
| A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive DisorderNCT07204314Vortioxetine tablets | Phase 3 | Locked · track to reveal | OngoingRecruiting | 180 est. | 30 Sept 2029 |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)NCT04419649Elritercept | Phase 2 | Locked · track to reveal | OngoingRecruiting | 160 est. | 30 Oct 2029 |
| ELRISE MFA Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking RuxolitinibNCT07623161Elritercept | Phase 3 | Not yet scored | OngoingRecruiting | 324 est. | 7 Dec 2029 |
| Continuation Study of Zasocitinib in Adults With Psoriatic ArthritisNCT07286058Zasocitinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,182 est. | 18 Dec 2029 |
| A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic PouchitisNCT06443502Vedolizumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 30 est. | 31 Jan 2030 |
| A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary ImmunodeficiencyNCT06565078Immune Globulin Subcutaneous (Human), 20% Solution | — | Not yet scored | OngoingRecruiting | 100 est. | 31 Mar 2030 |
| A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)NCT05582993Vonicog Alfa | Phase 3 | Locked · track to reveal | OngoingRecruiting | 24 est. | 11 Apr 2030 |
| A Study of Freeze-dried Human Protein C Concentrate (TAK-662) in Participants With Congenital Protein C DeficiencyNCT06590974Freeze-dried Human Protein C Concentrate | — | Not yet scored | OngoingRecruiting | 7 est. | 30 Jun 2030 |
| A Study of TAK-505 in Adults With Solid TumorsNCT07436728TAK-505 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 151 est. | 18 Aug 2030 |
| A Study of TAK-360 in People With Narcolepsy or Idiopathic HypersomniaNCT07646678TAK-360 | Phase 2 | Not yet scored | OngoingRecruiting | 500 est. | 15 Jun 2031 |